< Go to adacap.com| This site is for health care professionals only.

Neuroendocrine tumors (NETs)

  • Disease Education
  • MOA Resources
  • Clinical Trials
NET Expression infographic
LutetiumLu 177 dotatate mechanism of action video

[177Lu]Lu-DOTA-TATE Mechanism of Action

Explore the mechanism of action of targeted radioligand therapy (RLT) [177Lu]Lu-DOTA-TATE.

[177Lu]Lu-DOTA-TATE is being studied for (a) new use(s) for which efficacy and safety have not been established. There is no guarantee that [177Lu]Lu-DOTA-TATE will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.

Reimagining Neuroendocrine Tumors With Targeted Radioligands

Explore Clinical Trials

NETTER-2

SSTR-Targeted Therapy

A Phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 2 and Grade 3 advanced GEP-NET

NeoRay

GRPR-Targeted Therapy

A Phase I/IIa, open-label, multicenter study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry, and antitumor activity of [177Lu]Lu-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)

NETTER-P

SSTR-Targeted Therapy

A Phase II, multicenter, open-label study to evaluate safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NET) and pheochromocytomas and paragangliomas (PPGL)

LysaKare PASS

Arginine/Lysine Infusion

A Phase IV, multicenter, open-label, post-authorization safety study to evaluate the effect of L-arginine HCl/L-lysine HCL infusion on serum potassium levels in GEP-NET patients eligible for [177Lu]Lu-DOTA-TATE treatment

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Explore Compounds

[177Lu]Lu-DOTA-TATE

 

SSTR-targeted peptide receptor radionuclide therapy

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.

Explore Pipeline Explore Clinical Trials